MedTrace Logo

A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use

NCT03420040 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2018-02-05

No results posted yet for this study

Summary

A clinical study of the use of glargine insulin in 2 subjects with type two diabetes in China was carried out. The two kinds of injection methods were evaluated as subcutaneous injection of insulin glargine.

Conditions

Interventions

DEVICE

QS-M Needle Free Injector

The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection

DEVICE

Glargine pen

The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Qiuhe Ph.D Ji, M.D. · Department of Endocrinology, Xijing Hospital, Fourth Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-27
Primary Completion
2018-02-20
Completion
2018-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03420040 on ClinicalTrials.gov